Form 4: Vanda Pharmaceuticals Director Receives RSU Grant

Director Charles Cliff Duncan was granted 57,101 restricted stock units by Vanda Pharmaceuticals.

Summary

• Director Charles Cliff Duncan acquired 57,101 shares of Vanda Pharmaceuticals (VNDA) common stock via a restricted stock unit (RSU) award.
• The transaction occurred on April 22, 2026.
• The RSU award vests in four equal annual installments, beginning April 22, 2027, subject to continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is contingent upon the director maintaining continuous service to the issuer.

Future Outlook

The RSU award will vest in four equal annual installments starting April 22, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term board commitment and align leadership with shareholder value.

Comparison to Industry Standards

• The use of time-based RSU vesting over four years is consistent with standard executive and director compensation practices in the biotechnology sector.

Stakeholder Impact

• Shareholders: Minor dilution impact upon future vesting of shares.

Next Steps

• First annual vesting of the RSU award on April 22, 2027.

Key Dates

Keywords

Vanda Pharmaceuticals, VNDA, Form 4, Insider Trading, Director Compensation, Restricted Stock Units